MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Marinus Pharmaceuticals Company Profile (NASDAQ:MRNS)

Consensus Ratings for Marinus Pharmaceuticals (NASDAQ:MRNS) (?)
Ratings Breakdown: 4 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $9.38 (610.23% upside)

Analysts' Ratings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Show:
DateFirmActionRatingPrice TargetActions
6/30/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Goldman Sachs Group Inc.DowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Oppenheimer Holdings Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$14.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2015Janney Montgomery ScottReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/26/2014JMP SecuritiesInitiated CoverageOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/2/2016($0.41)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2016Q416($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015($0.51)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015($0.51)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015($0.47)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015($0.39)$0.62ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q3 14($0.50)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Marinus Pharmaceuticals (NASDAQ:MRNS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.40)($0.37)($0.39)
Q2 20162($0.40)($0.39)($0.40)
Q3 20162($0.39)($0.38)($0.39)
Q4 20162($0.39)($0.37)($0.38)
(Data provided by Zacks Investment Research)
Dividend History for Marinus Pharmaceuticals (NASDAQ:MRNS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Marinus Pharmaceuticals (NASDAQ:MRNS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/21/2015Gail M FarfelInsiderSell30,000$9.48$284,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Domain Partners Vi, L.P.Major ShareholderBuy419,744$8.00$3,357,952.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Stephen M BlochDirectorBuy625,000$8.00$5,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Marinus Pharmaceuticals (NASDAQ:MRNS)
DateHeadline
06/30/16 08:10 AMMarinus Pharma (MRNS) Says Primary Endpoint Not Met in Ganaxolone Phase 2 Exploratory Study
06/29/16 05:10 PMWatching Stock Volatility for: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
06/29/16 05:10 PMFrontline Matters in Notice- Marinus Pharmaceuticals (NASDAQ:MRNS), SolarCity (NASDAQ:SCTY), Iron Mountain ... - Seneca Globe
06/29/16 08:05 AMMarinus Pharmaceuticals, Inc. (MRNS) Updated Price Targets - FTSE News
06/28/16 05:09 PMCovering the Bases on Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS): Where is the Stock Going? - Press Telegraph
06/28/16 05:09 PMCheck on Share Volatility: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Engelwood Daily
06/28/16 05:09 PMExpectations Surging for Marinus Pharma (MRNS) Trial Data; Regulus Therapeutics (RGLS) Crashes On FDA's ... - Galaxy Stocks (press release) (registration)
06/28/16 05:09 PMMarinus Pharma (MRNS) Says Primary Endpoint Not Met in Ganaxolone Phase 2 Exploratory Study - StreetInsider.com
06/28/16 10:08 AMMarinus (MRNS) Plans Conference Call to Reports Results From Phase 2 Study of Ganaxolone in Children with Fragile X
06/28/16 10:08 AMResults from Phase 2 Exploratory Clinical Study Support Continued Development of Ganaxolone in Fragile X Syndrome
06/28/16 10:08 AMExpectations Surging for Marinus Pharma (MRNS) Trial Data; Regulus Therapeutics (RGLS) Crashes On FDA’s Determination
06/27/16 05:10 PMMarinus Pharmaceuticals, Inc. (MRNS) Broker Price Targets For The Coming Week - Fiscal Standard
06/27/16 03:21 PMMarinus Pharmaceuticals to Host Conference Call on Tuesday, June 28 - [at noodls] - RADNOR, Pa., June 27, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric ...
06/25/16 04:52 PMShare Volatility Check for: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Press Telegraph
06/25/16 04:52 PMAre Analysts Bullish Marinus Pharmaceuticals Inc (NASDAQ:MRNS) After Last Week? - Press Telegraph
06/23/16 05:46 PMStrong Sell Calls Recommendations For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) At 0 - Investor Newswire
06/23/16 07:58 AMMarinus Pharma (MRNS) Commences Dosing in Ganaxolone IV Phase 1 as SE Treatment
06/22/16 05:09 PMMarinus Pharma (MRNS) Commences Dosing in Ganaxolone IV Phase 1 as SE Treatment - StreetInsider.com
06/22/16 06:39 AMMarinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV - [at noodls] - RADNOR, Pa., June 22, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric ...
06/20/16 04:46 AMAnalyst Views For The Week Ahead: Marinus Pharmaceuticals, Inc. (MRNS) - Fiscal Standard
06/19/16 09:15 AM6 Companies That Destroyed Shareholders Last Week -
06/16/16 05:26 PMStrong Buy Calls Count For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) At 1 - Investor Newswire
06/15/16 09:52 AMOverview of Price Moves: Kindred Healthcare, Inc. (NYSE:KND) , Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Street Updates
06/15/16 09:52 AMAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) & Marinus Pharmaceuticals (NASDAQ:MRNS) Movers to Watch - Wall Street 24
06/14/16 10:04 AMMarinus Pharmaceuticals | $MRNS Stock | Shares Plummet On Disappointing Trial Results - TickerTV News (press release)
06/14/16 10:04 AMBuzz Stocks: Smith & Wesson Holding Corp, Marinus Pharmaceuticals Inc, and LinkedIn Corp - Schaeffers Research (blog)
06/14/16 10:04 AMPrice Target Summary Report: St. Jude Medical Inc. (NYSE:STJ), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Beacon Chronicle
06/14/16 10:04 AMNotable Analyst Rating Changes: Marinus Pharmaceuticals Inc (MRNS) and Endo International plc – Ordinary Shares ... - Smarter Analyst
06/14/16 08:46 AMMarinus Stock Down on Dismal Phase III Data on Ganaxolone -
06/14/16 05:05 AMMarinus Pharmaceuticals downgraded by RBC Capital Mkts -
06/13/16 04:55 PMPre-Open Stock Movers 06/13: (EBIO) (LNKD) (AGIO) Higher; (MRNS) (EMES) (WFT) Lower (more...)
06/13/16 04:55 PMEpilepsy Drug Maker Marinus (MRNS) Sinks on Disappointing Late-Stage Data
06/13/16 04:55 PMWhy Marinus Pharmaceuticals Shares Are Sliding
06/13/16 04:55 PMMarinus Pharmaceuticals Inc. (MRNS) Is Sinking After Phase 3 Study Failed
06/13/16 01:57 PM7 Biggest Mid-Day Losers For Monday - Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares declined 68.35 percent to $1.69 as the company reported top-line results from Phase 3 trial in adult focal onset seizures. In this trial, ganaxolone did not meet the primary endpoint. New Concept Energy, Inc. (NYSE: GBR) dropped 26.08 percent to $1.95. Argos Therapeutics Inc (NASDAQ: ARGS) shares fell 17.54 percent to ...Full story available on Benzinga.com
06/13/16 08:12 AMMarinus Pharma (MRNS) Announces Ganaxolone Phase 3 Missed Primary Endpoint in Adult Focal Onset Seizures - StreetInsider.com
06/13/16 07:47 AMMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/13/16 07:45 AMRadnor biopharm's stock plunges following disappointing seizure treatment study -
06/13/16 07:04 AMMarinus Pharma's trial of treatment for drug-resistant epilepsy failed to meet goals -
06/13/16 06:48 AMMarinus' drug for focal onset seizures fails in late-stage study -
06/13/16 06:39 AMMarinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures - [at noodls] - RADNOR, Pa., June 13, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric ...
06/08/16 05:02 PMMarinus Pharmaceuticals, Inc. :MRNS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/04/16 08:04 AMMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Stock Update & Estimates - Stock Tick Tock
06/02/16 08:12 AMInsiders Are Gradually Buying Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - HNN - Insiders Are Gradually Buying Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)HNNAccording to the latest SEC filings, insiders at Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have increased their position in the stock by 2.08% over the past 6 months. Insiders now own 0.90% of total outstanding shares. There are both legal and ...How Analysts Feel About Marinus Pharmaceuticals Inc After Today's Huge Decline?The Postall 2 news articles »
05/31/16 05:31 PMStrong Sell Calls Count For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) At 0 - Investor Newswire - Strong Sell Calls Count For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) At 0Investor NewswireMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has a total of 3 Strong Buy calls and 0 Strong Sell advises as of 2016-05-30. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
05/31/16 12:12 AMMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) 1-Year High At $20.72 - Investor Newswire - Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) 1-Year High At $20.72Investor NewswireYesterday, the stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) closed at $5.29 after opening at $5.28 and registering high of $5.44 and low of $5.00. The last price is $-15.41 away 1-year high of $20.72 and $1.31 away from low of $4.00 during same ...and more »
05/02/16 06:40 AMMarinus Pharmaceuticals posts 1Q loss -
05/02/16 06:40 AMMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results - [at noodls] - RADNOR, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric ...
04/21/16 03:54 PMMARINUS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
04/15/16 06:36 AMMarinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus - [at noodls] - RADNOR, Pa., April 15, 2016 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric ...
About Marinus Pharmaceuticals

Marinus Pharmaceuticals logoMarinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MRNS
  • CUSIP:
Key Metrics:
  • Previous Close: $1.32
  • 50 Day Moving Average: $3.67
  • 200 Day Moving Average: $5.16
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $25.75M
  • Current Quarter EPS Consensus Estimate: $-1.47 EPS
Additional Links:
Marinus Pharmaceuticals (NASDAQ:MRNS) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha